Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Nicht-pharmakologische Behandlungen für Parasomnien (Hypnosomnia)

5. November 2026 aktualisiert von: Chantal Berna Renella

Bewertung der Wirksamkeit nicht-pharmakologischer Behandlungen für Parasomnien: eine randomisierte kontrollierte Studie

The goal of this clinical trial is to compare the efficacy of non-pharmacological treatments (medical hypnosis and standard treatment) in patients with a non-REM parasomnia diagnosis (N=60).

Participants are randomly assigned to one of the two treatments. Treatment consists of 3 sessions. Participants receiving the standard treatment (i.e., sleep hygiene and episode risk reduction) may subsequently receive medical hypnosis.

Participation in the study involves 5 visits in total: 3 treatment visits and 2 study visits to the hospital (CHUV).

  • An initial study visit to provide information and collect questionnaires prior to the start of treatment. An initial non-therapeutic hypnosis session will be carried out during electroencephalography (EEG). Estimated duration: 2h.
  • A second study visit at the end of treatment, including questionnaires about your sleep and treatment. A shorter non-therapeutic hypnosis session and a second EEG will be performed. Estimated duration: 1h30. This visit may also be followed by an overnight polysomnography, according to patient's choice (if performed, estimated total duration 12 hrs).

This study also involves monitoring patients' sleep for 10 nights before and after treatment: they will fill in a sleep diary and use an infrared camera.

For the validation of the EEG methodology, healthy volunteers (N=50) will complete a unique visit resembling the initial study visit of patients.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

110

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Canton of Vaud
      • Lausanne, Canton of Vaud, Schweiz, 1005
        • Centre hospitalier universitaire vaudois (CHUV)

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Patients with NREM parasomnia (N=60):

Inclusion Criteria:

  • Non-REM parasomnias diagnosis according to the international classification disease of sleep disorders
  • Willling and able to give informed consent
  • Reporting at least one parasomniac episode per month
  • Reporting at least one parasomniac episode the month prior

Exclusion Criteria:

  • Refusal to use the home video recording device
  • Current or planned intake (during the next 2 months) of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines)
  • A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia)
  • A comorbid sleep disorder (e.g., apnea-hypopnea index (AHI) >= 20/hour, REM sleep behaviour disorder, restless legs syndrome with symptoms more than 2 days/week)
  • A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder)

Healthy volunteers (N=50):

Inclusion Criteria:

- Adult (≥ 18 yo) willing and able to give informed consent.

Exclusion criteria:

  • Presence of NREM parasomnias diagnosis, or any other concomitant sleep disorder;
  • Current intake of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines);
  • A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia);
  • A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder);
  • Current history of psychiatric or neurological disorders (e.g., migraines).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Medical hypnosis (HYP) (N=30)

3 medical hypnosis interventions

Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)

Aktiver Komparator: Standard Of Care (SOC) (N=30)

3 standard of care quality and sleep safety interventions

Sleep hygiene and safety education session

Kein Eingriff: Healthy volunteers (N=50)

Unique EEG visit resembling the initial study visit of patients with NREM parasomnias

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change, from pre-treatment, of mean number of parasomniac episodes at 9 weeks
Zeitfenster: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment

Parasomniac episodes scored on infrared home video recording

Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Duration of parasomniac episodes
Zeitfenster: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment

Using home video recording

Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment
Rate of confusional arousals, sleepwalking and sleep terrors episodes
Zeitfenster: Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment

Categorization of parasomniac episodes' complexity (confusional arousals, sleepwalking, sleep terrors) using home video recording

Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment
Incidence of emotions related to parasomniac episodes
Zeitfenster: Through study duration, an average of 9 weeks

Emotional impact of parasomniac episodes using questionnaires (e.g., What emotions did you feel during these episodes?; Do you have negative emotions related to your parasomnias?)

Through study duration, an average of 9 weeks
Quality of life score
Zeitfenster: At Day 0, Week 11 and Week 18

Using a standardized questionnaire: World Health Organization Quality Of Life-BREF (WHOQOL-BREF). Score ranging from 0 to 100, higher score denoting greater perceived quality of life.

At Day 0, Week 11 and Week 18
Anxiety and depression scores
Zeitfenster: At Day 0 and Week 11

Using a standardized questionnaire: Hospital Anxiety and Depression Scale (HADS). Subscale score ranging from 3 to 21, score >8 denotes anxiety or depression.

At Day 0 and Week 11
Traumatic events score
Zeitfenster: At Day 0

Using a standardized questionnaire: Life Event Checklist for DSM-5 (LEC-5). It does not yield a total score or a composite score.

At Day 0
Fatigue score
Zeitfenster: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Pichot's fatigue scale. Score ranging from 0 to 32, score >22 denotes excessive fatigue.

At Week 2, Week 11 and Week 18
Sleepiness score
Zeitfenster: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Epworth Sleepiness Scale (ESS). Score ranging from 0 to 24, higher score denoting higher daytime sleepiness.

At Week 2, Week 11 and Week 18
Sleep quality score
Zeitfenster: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Pittsburgh Sleep Quality Index (PSQI). Score ranging from 0 to 21, higher score denoting greater acute sleep disturbances.

At Week 2, Week 11 and Week 18
Severity of arousal disorders score
Zeitfenster: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Paris Arousal Disorders Severity Scale (PADSS). Score ranging from 0 to 50, higher score denoting more severed disorders.

At Week 2, Week 11 and Week 18
Circadian typology score
Zeitfenster: At Week 2, Week 11 and Week 18

Using a standardized questionnaire: Horne & Östberg questionnaire. Score ranging from 16 to 86, higher score denoting morningness and lower score eveningness.

At Week 2, Week 11 and Week 18
Changes in sleep architecture
Zeitfenster: At Day 0 and Week 11

Using power spectral sleep EEG analysis including delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), sigma (12-16 Hz), and beta (18-30 Hz) frequency bands with Titanium, Embla®, NOX-A1®.

At Day 0 and Week 11
Sleep eye movements
Zeitfenster: At Week 11 (optional)

Using power spectral sleep EOG analysis (left and right) with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep muscles activity
Zeitfenster: At Week 11 (optional)

Using power spectral sleep EMG analysis (chin and anterior tibialis muscle) with Titanium, Embla®, NOX-A1®

At Week 11 (optional)
Sleep cardiac activity
Zeitfenster: At Week 11 (optional)

Using power spectral sleep ECG analysis (P wave, QRS complex, QT interval, PR interval...) with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep oxygen saturation
Zeitfenster: At Week 11 (optional)

Using sleep oxygen saturation measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep airflow
Zeitfenster: At Week 11 (optional)

Using sleep airflow measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Sleep respiratory efforts
Zeitfenster: At Week 11 (optional)

Using abdominal and thoracic respiratory efforts measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Snoring
Zeitfenster: At Week 11 (optional)

Using snoring measures with Titanium, Embla®, NOX-A1®.

At Week 11 (optional)
Changes in imagery processes
Zeitfenster: At Day 0 and Week 11 for patients.

Using patients' EEG measures (N=60) collected with a 124-channel waveguardTMoriginal EEG cap and during 3-minute pleasant imagery suggestion audio recordings.

At Day 0 and Week 11 for patients.
Validation of the EEG methodology for the imagery processes recordings
Zeitfenster: At Day 0

Using healthy volunteers' EEG measures (N=50) collected with a 124-channel waveguardTMoriginal EEG and during 5-minute pleasant imagery suggestion audio recordings.

At Day 0

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Chantal Berna Renella, Prof, CHUV

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

30. August 2023

Primärer Abschluss (Tatsächlich)

19. Februar 2026

Studienabschluss (Tatsächlich)

15. August 2026

Studienanmeldedaten

Zuerst eingereicht

2. Juni 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. Juli 2023

Zuerst gepostet (Tatsächlich)

20. Juli 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • CER-VD 2023-01007

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .